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Amongst congenital heart diseases (CHD) none has undergone a more drastic change in 
diagnostic approach, management and outcomes over the last 30 years than hypoplastic left 
heart syndrome (HLHS) with ‘comfort care’ replaced as the predominant form of 
management by a palliative surgical treatment pathway1. The outcomes of palliative 
procedures for HLHS have been well documented but the longer-term picture is less clear.  
The UKs National Congenital Heart Diseases Audit (NCHDA) captures every procedure 
undertaken for CHD and updated life status for patients resident in England and Wales 
based on death certifications. From this dataset we identified patients born between 2000 
and 2015 who fulfilled the criteria for HLHS: a small left ventricle, stenosis or atresia of the 
left sided heart valves, normally aligned great arteries and no common atrioventricular 
junction2. All HLHS patients require surgical palliation with a traditional Norwood or hybrid 
pathway or heart transplantation to survive and hence we were able to use procedure 
information in combination with diagnostic information to identify HLHS patients within the 
NCHDA dataset using the International Paediatric and Congenital Cardiac Codes. As the 
NCHDA is a procedure-based dataset, patients with HLHS who did not undergo any 
interventional treatment are not included. Since the Hybrid procedure was introduced in the 
UK in 2006, we considered two eras for analyses dating up to and after 2006.  
The surgical and catheterization procedures undertaken were classified as: 
 Pathway procedures consistent with HLHS treatment including the Norwood (Stage 
1), Glenn (Stage 2) and Fontan (Stage 3) procedures of traditional surgical palliation; 
the hybrid procedure, the comprehensive Stage 2; and transplantation procedures.  
 Pre-pathway procedures either required to stabilise very sick HLHS neonates such 
as pulmonary artery banding and interventions for restrictive atrial septum or 
interventions to the aortic valve or arch in neonates with hypoplastic left ventricle 
where a failed biventricular approach was evident based on subsequent events. 
 Off-pathway procedures that may be required in patients with HLHS such as 
revision of arterial shunt or Sano or stenting or dilation of residual or re-coarctation3. 
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Whilst we report transplant procedures within our description of pathways and outcomes for 
HLHS, transplant did not represent an endpoint in our primary analysis of condition-based 
survival. Survival analysis was carried out using the Kaplan-Meier approach, with death 
representing failure. Data were analysed using the Stata 13 statistical software package.  
The study was approved by the NCHDA Research Committee and by the National Health 
Service (NHS) Healthcare Quality Improvement Partnership (Study number 14CONG03). 
Further ethics committee approval and patient consent were waived. 
Of 976 patients with HLHS, 9.6% had a pre-pathway intervention, this carrying the highest 
in-hospital mortality of 34.0%, 89.5% embarked on a traditional surgical pathway of staged 
palliation and 6.4% of smaller and more complex infants embarked on a hybrid pathway4.  
The outcomes among patients that followed different trajectories are shown in Figure 1. For 
20 of the patients lost to follow-up, survival was censored at the last known hospital 
discharge. 
The in-hospital mortality for the primary procedure (Norwood or hybrid) was 22.9% (95% CI 
20.2%-25.7%), for Stage 2 Glenn was 3.6% (95% CI 2.2%-5.4%) and for Stage 3 Fontan 
was 1.2% (95% CI 0.3%-3.1%). The interstage mortality between primary procedure and 
Stage 2 (or comprehensive Stage 2) was 13.0% (95% CI 10.6%-15.6%) and between Stage 
2 (or comprehensive Stage 2) and Stage 3 was 7.3% (95% CI 5.2%-9.9%). On comparison 
of outcomes by era, the only statistically significant change in mortality at different stages 
was a reduction in in-hospital mortality following Norwood (Stage 1) surgery.  
Kaplan-Meier survival inclusive of all patients was 60.7% (95% CI 57.5%-63.7%) at 1 year 
and 56.3% (95% CI 53.0%-59.5%) at 5 years. The log rank test suggested better survival in 
patients undergoing a traditional surgical pathway (including all those undergoing pre-
pathway procedures) in the later era (p=0.088). Since the hybrid procedure was introduced 
in 2006 (and noting the increased complexity amongst patients undergoing hybrid pathway), 
survival on the traditional pathway has been higher (p=0.050). 
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There was at least one off-pathway procedure in 44.6% of patients. The rate for off-pathway 
cardiac surgery was 6 per 100 patient-years and the rate for off-pathway interventional 
catheterization was 16 per 100 patient-years, with a significant increase between eras 
(p<0.001).  
The mandatory national audit of cardiac procedures and the independent tracking of survival 
were essential prerequisites for this population based study, which captures the outcomes 
for all patients with HLHS who underwent at least one cardiac procedure between 2000 and 
2015 in England and Wales. Early post-operative survival rates have improved over time and 
are now inadequate as indices of quality, or to inform clinicians and families about outcomes 
and events following a diagnosis of HLHS. 
Treatment pathways amongst patients with HLHS are highly variable and complex. The 
analysis of longer-term outcome based on diagnosis gives a more complete and useful 
picture than short-term outcomes based on procedure, and may inform quality improvement 
initiatives. The outcome for HLHS treated in the England and Wales compares well with 
international standards3,5. 
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 Figure 1: Interventions and outcomes for 976 English and Welsh patients with HLHS 
between 2000 and 2015. All patients who embarked on the traditional surgical treatment 
pathway (874, 89.5%of the cohort) are shown in purple, those who embarked on a hybrid 
pathway (62, 6.4% of the cohort) in orange. Patients who had a Stage 1 procedure following 
their hybrid procedure (18, 29.0% of hybrids) are shown in blue from that point. The 
trajectories of patients that had pre pathway procedures (94, 9.6% of the cohort) are shown 
in green to the point where they join the traditional or hybrid pathway. Heart transplants are 
represented with a heart symbol 
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